A5012674451- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Cancer, Stress, Anesthesia, and Immune Response
- Helicobacter pylori-related gastroenterology studies
- Colorectal and Anal Carcinomas
- Peptidase Inhibition and Analysis
- Lung Cancer Research Studies
- Diet, Metabolism, and Disease
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Gastroesophageal reflux and treatments
Debiopharm (Switzerland)
2022-2024
Xevinapant is an orally available inhibitor of apoptosis proteins (IAP) inhibitor. Preclinical data suggest that IAP antagonism may synergize with immune checkpoint blockers by modulating the NFκB pathway in cells.
Abstract INTRODUCTION: Xevinapant is an oral IAP (inhibitor of apoptosis protein) inhibitor designed to restore cancer cell sensitivity apoptosis, thereby enhancing the efficacy chemoradiotherapy (CRT) and radiotherapy (RT). 200 mg/d (d1-14, Q3W) + CRT showed clinical benefit vs placebo in a phase 2 study patients with locally advanced squamous carcinoma head neck (LA SCCHN; NCT02022098). Two 3 studies are currently ongoing evaluating xevinapant combination (TrilynX; NCT04459715) or RT (XRay...
<p>Supplemetary figures S1, S2 and S3</p>
<p>Supplemetary figures S1, S2 and S3</p>
<p>Representativeness</p>
<div>AbstractPurpose:<p>Xevinapant is an orally available inhibitor of apoptosis proteins (IAP) inhibitor. Preclinical data suggest that IAP antagonism may synergize with immune checkpoint blockers by modulating the NFκB pathway in cells.</p>Patients and Methods:<p>Adult patients non–high microsatellite instability advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) or colorectal cancer were enrolled this phase Ib/II study received pembrolizumab 200 mg every 3...
<p>Representativeness</p>
<div>AbstractPurpose:<p>Xevinapant is an orally available inhibitor of apoptosis proteins (IAP) inhibitor. Preclinical data suggest that IAP antagonism may synergize with immune checkpoint blockers by modulating the NFκB pathway in cells.</p>Patients and Methods:<p>Adult patients non–high microsatellite instability advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) or colorectal cancer were enrolled this phase Ib/II study received pembrolizumab 200 mg every 3...
Abstract BACKGROUND: Combining anti-PD-1/L1 antibodies and agents that restore cancer cell susceptibility to apoptosis may enhance antitumor activity. We report results from a phase 1b dose-expansion cohort of xevinapant, first-in-class, oral, small-molecule IAP (inhibitor protein) inhibitor restores sensitivity apoptosis, avelumab (anti-PD-L1) in pts with advanced NSCLC. METHODS: The recommended 2 dose (RP2D; 28-day cycles xevinapant 200 mg/day [days 1-10 15-24] + 10 mg/kg 1 15]) was...
<h3>Background</h3> Anticancer agents that render cancer cells susceptible to apoptosis and increase antitumor immunity may enhance clinical responses immune checkpoint inhibitors. In this phase 1b/2 trial, we investigated the activity safety of xevinapant, a first-in-class, potent, oral, small-molecule inhibitor proteins which restores cell sensitivity apoptosis, in combination with anti-PD-1 antibody nivolumab. <h3>Methods</h3> Eligible patients had histologically confirmed advanced or...